ijms-logo

Journal Browser

Journal Browser

Mechanisms of Diabetic Cardiomyopathy

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pathology, Diagnostics, and Therapeutics".

Deadline for manuscript submissions: 30 December 2024 | Viewed by 1061

Special Issue Editor


E-Mail Website
Guest Editor
Department of Pharmacology, University Medical Center, Johannes Gutenberg University, 55131 Mainz, Germany
Interests: cardiovascular system; lower urinary tract

Special Issue Information

Dear Colleagues,

When phosphodiesterase type 4 inhibitors and β-adrenoceptor agonists were found to be detrimental in chronic heart failure treatment, new treatments did not become available for a long time. This has changed with the advent of a neprilysin inhibitor/angiotensin receptor antagonist combination and, most recently, SGLT4 inhibitors. These new drug classes have also opened up avenues to more specifically treat cardiomyopathy as it occurs as a consequence of diabetes.

This Special Issue will welcome manuscripts exploring the pathophysiology and treatment of diabetic cardiomyopathy based on applicable cellular models, animal models and human isolated tissues; clinical studies in humans are also welcome if they provide mechanistic insight. Similarly, work on established drugs and drug targets and insight on potential new treatments will be welcome. Studies providing molecular and mechanistic insight will be particularly welcome.

Prof. Dr. Martin Michel
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • diabetes
  • cardiomyopathy
  • animal models
  • novel treatments
  • pathophyiology
  • SGLT2 inhibitors
  • neprilysin inhibitors

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

20 pages, 6050 KiB  
Article
Sacubitril/Valsartan Combination Partially Improves Cardiac Systolic, but Not Diastolic, Function through β-AR Responsiveness in a Rat Model of Type 2 Diabetes
by Betul R. Erdogan, Zeynep E. Yesilyurt-Dirican, Irem Karaomerlioglu, Ayhanim Elif Muderrisoglu, Kadir Sevim, Martin C. Michel and Ebru Arioglu-Inan
Int. J. Mol. Sci. 2024, 25(19), 10617; https://doi.org/10.3390/ijms251910617 - 2 Oct 2024
Viewed by 805
Abstract
Cardiovascular complications are the major cause of diabetes mellitus-related morbidity and mortality. Increased renin–angiotensin–aldosterone system activity and decreased β-adrenergic receptor (β-AR) responsiveness contribute to diabetic cardiac dysfunction. We evaluated the effect of sacubitril/valsartan (neprilysin inhibitor plus angiotensin receptor antagonist combination) and valsartan treatments [...] Read more.
Cardiovascular complications are the major cause of diabetes mellitus-related morbidity and mortality. Increased renin–angiotensin–aldosterone system activity and decreased β-adrenergic receptor (β-AR) responsiveness contribute to diabetic cardiac dysfunction. We evaluated the effect of sacubitril/valsartan (neprilysin inhibitor plus angiotensin receptor antagonist combination) and valsartan treatments on the diabetic cardiac function through β-AR responsiveness and on protein expression of diastolic components. Six-week-old male Sprague Dawley rats were divided into control, diabetic, sacubitril/valsartan (68 mg/kg)-, and valsartan-treated (31 mg/kg) diabetic groups. Diabetes was induced by a high-fat diet plus low-dose streptozotocin (30 mg/kg, intraperitoneal). After 10 weeks of diabetes, rats were treated for 4 weeks. Systolic/diastolic function was assessed by in vivo echocardiography and pressure–volume loop analysis. β-AR-mediated responsiveness was assessed by in vitro papillary muscle and Langendorff heart experiments. Protein expression of sarcoplasmic reticulum calcium ATPase2a, phospholamban, and phosphorylated phospholamban was determined by Western blot. Sacubitril/valsartan improved ejection fraction and fractional shortening to a similar extent as valsartan alone. None of the treatments affected in vivo diastolic parameters or the expression of related proteins. β1-/β2-AR-mediated responsiveness was partially restored in treated animals. β3-AR-mediated cardiac relaxation (an indicator of diastolic function) responses were comparable among groups. The beneficial effect of sacubitril/valsartan on systolic function may be attributed to improved β1-/β2-AR responsiveness. Full article
(This article belongs to the Special Issue Mechanisms of Diabetic Cardiomyopathy)
Show Figures

Figure 1

Back to TopTop